Drug Database · Clinicians

Diclofenac

Brands (93) Voren, Boren, Cataflam…Show all

US brand (reference label): Diclofenac Sodium; not a Philippine-registered brand.

Non-steroidal anti-inflammatory Drug/NSAID (acetic acid derivative and related substance); Non-steroidal anti-inflammatory drugs (NSAID’s); and others PH FDA category

Avoid in advanced CKDRx · Prescription drugOTC · Over-the-counter117 PH productsPNF-listed Kidney dosing reviewed
Dispensing: Over-the-counter (OTC) · Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 0e5c6669-390f-4c32-b9b8-13ed3c517462, version date October 23, 2026 (Diclofenac Sodium · Umedica Laboratories USA Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • For relief of the signs and symptoms of osteoarthritis
  • For relief of the signs and symptoms of rheumatoid arthritis For acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation).

Diclofenac sodium delayed-release tablets are indicated: For relief of the signs and symptoms of osteoarthritis For relief of the signs and symptoms of rheumatoid arthritis For acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis

Contraindications

  • Hypersensitivity to the drug
  • Asthma, urticaria or allergic-type reaction after aspirin or other NSAIDs
  • Setting of coronary artery bypass graft (CABG) surgery
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

CONTRAINDICATIONS Diclofenac sodium delayed-release tablets are contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see WARNINGS; Anaphylactic Reactions, Serious Skin Reactions). History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.

Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients (see WARNINGS; Anaphylactic Reactions, PRECAUTIONS; Exacerbation of Asthma Related to Aspirin Sensitivity). In the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS; Cardiovascular Thrombotic Events).

Dosing: Adult

  • Osteoarthritis: 100 to 150 mg/day in divided doses (50 mg two or three times daily, or 75 mg twice daily)
  • Rheumatoid arthritis: 150 to 200 mg/day in divided doses
  • Ankylosing spondylitis: 100 to 125 mg/day (25 mg four times daily, plus 25 mg at bedtime if needed)
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation).

After observing the response to initial therapy with diclofenac sodium delayed-release tablets, the dose and frequency should be adjusted to suit an individual patient’s needs. For the relief of osteoarthritis, the recommended dosage is 100 to 150 mg/day in divided doses (50 mg twice a day or three times a day, or 75 mg twice a day).

For the relief of rheumatoid arthritis, the recommended dosage is 150 to 200 mg/day in divided doses (50 mg three times a day. or four times a day, or 75 mg twice a day.). For the relief of ankylosing spondylitis, the recommended dosage is 100 to 125 mg/day, administered as 25 mg four times a day, with an extra 25-mg dose at bedtime if necessary.

Different formulations of diclofenac (diclofenac sodium enteric-coated tablets; diclofenac sodium extended-release tablets, diclofenac potassium immediate-release tablets) are not necessarily bioequivalent even if the milligram strength is the same.

Dosing: Altered kidney function

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) cleared by liver metabolism; its pharmacokinetics do not change in kidney impairment. The kidney concern is injury, not accumulation: the US label advises avoiding it in advanced kidney disease unless benefits outweigh the risk and monitoring kidney function, potassium and blood pressure in anyone at risk.

Kidney function measure: Label PK study used inulin clearance (60–90, 30–60, <30 mL/min); warnings use 'advanced renal disease' without a number. Mapping 'advanced' to CrCl <30 is our judgment.

Show full dosing details
CrCl ≥60 mL/min
Usual dose by indication: osteoarthritis 100 to 150 mg/day, rheumatoid arthritis 150 to 200 mg/day, in divided doses (label). Lowest effective dose, shortest duration.
CrCl 30–59 mL/min
No dose change (pharmacokinetics unchanged; label). Kidney impairment raises the risk of NSAID kidney injury: monitor creatinine, potassium and blood pressure; avoid volume depletion and the ACE inhibitor or ARB plus diuretic combination.
CrCl 15–29 mL/min
No information from controlled studies in advanced kidney disease; avoid unless benefits outweigh the risk of worsening kidney function, and if used monitor kidney function (label, Renal Toxicity). Pharmacokinetics are unchanged in kidney impairment (inulin clearance down to <30 mL/min), so the risk is kidney injury, not accumulation.
CrCl <15 mL/min (not on dialysis)
No information from controlled studies in advanced kidney disease; avoid unless benefits outweigh the risk of worsening kidney function, and if used monitor kidney function (label, Renal Toxicity). Pharmacokinetics are unchanged in kidney impairment (inulin clearance down to <30 mL/min), so the risk is kidney injury, not accumulation.
Hemodialysis (intermittent)
Avoid unless benefits outweigh the risk (advanced kidney disease; label). Not removed by dialysis (over 99% protein-bound). NSAIDs may hasten loss of residual kidney function.
Peritoneal dialysis
Avoid unless benefits outweigh the risk (label). NSAIDs may hasten loss of residual kidney function.
CRRT
Avoid: NSAIDs can worsen acute kidney injury.
  • Dialyzable? Unlikely: hemodialysis may not be useful because of high protein binding (over 99%; label).
  • Monitoring Creatinine, potassium and blood pressure in CKD, heart failure, liver disease, dehydration or with ACE inhibitors, ARBs or diuretics. Liver enzymes within 4 to 8 weeks of starting long-term use (diclofenac hepatotoxicity warning).
Children (kidney dosing)
eGFR ≥60
Not approved for children; kidney dosing not applicable.
eGFR 30–59
Not approved for children; kidney dosing not applicable.
eGFR 15–29
Not approved for children; kidney dosing not applicable.
eGFR <15 (not on dialysis)
Not approved for children; kidney dosing not applicable.
Hemodialysis (intermittent)
Not approved for children; kidney dosing not applicable.
Peritoneal dialysis
Not approved for children; kidney dosing not applicable.
CRRT
Not approved for children; kidney dosing not applicable.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

Renal Impairment: Diclofenac pharmacokinetics has been investigated in subjects with renal insufficiency. No differences in the pharmacokinetics of diclofenac have been detected in studies of patients with renal impairment. In patients with renal impairment (inulin clearance 60 to 90, 30 to 60, and less than 30 mL/min; N = 6 in each group), area under the curve (AUC) values and elimination rate were comparable to those in healthy subjects.

Dosing: Pediatric

Approved ages
Not established in pediatric patients (label).
Usual dose
Not established.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Enteric-coated tablet: 25 mg, 50 mg
  • Solution for injection: 25 mg/mL
  • ) solution for injection: 25 mg/mL (75 mg/3 mL
  • Rectal suppository: 12.5 mg, 25 mg, 50 mg, 100 mg
  • Sustained-release tablet: 100 mg
  • Film-coated tablet: 50 mg, 100 mg
  • Gel: 1 g/100 g, 10 mg/g
  • Topical gel: 10 mg/g, 18.6 mg/g
  • Diclofenac diethylamine) topical gel: 10 mg/g (1 % w/w) (equivalent to 11.6 mg, 10 mg/g (equivalent to 11.6 mg/g
  • Enteric film-coated tablet: 50 mg

and 15 more forms; see the products table.

Registered products in the Philippines

117 products registered with the Food and Drug Administration (FDA) Philippines list Diclofenac as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Diclofenac Diethylamine (8 products, possible match).

Verify on PH FDA portal

All registered products117
Philippine FDA-registered products for Diclofenac
Package insert
AcuflamDiclofenac Sodium
10 mg/g (1 % w/w) Topical SprayOpaque white HDPE Bottle with HDPE cap x 60 mL (Box of 1's)
OTC
Unison Laboratories Co., Ltd.Thailand
JustRight Healthcare Inc.
DR-XY46381
Aug 20, 2028
Alisakit PlasterDiclofenac (as Sodium)
15 mg PlasterPolyethylene-aluminum Pouch x 7's (Box of 50 pouches)
Rx
Sinil Pharmaceutical Co., Ltd.Korea
Ambica International Corporation
DR-XY49206
Sep 13, 2029
ArnilDiclofenac Sodium (as diethylamine)
1 g/100 g GelAluminum Tube x 20 g (Box of 1's)
Rx
Brookes Pharma Private LimitedPakistan
Sahar International Trading Inc.
DR-XY43001
Nov 22, 2028
Atornac KDiclofenac Potassium
50 mg Enteric-Coated TabletAlu-PVC Blister Pack x 10's (Box of 30's)
Rx
Pell Tech Health Care Pvt. Ltd.India
Ambica International Corporation
DRP-9933
Aug 14, 2030
BlifecDiclofenac Sodium
25 mg/mL (75 mg/3 mL) Solution For Injection (I.M.)USP Type I Amber Glass Ampoule in a PVC Tray x 3 mL (Box of 10's)
Rx
Makcur Laboratories LimitedIndia
Afree Pharmaceutical Distribution Corp.
DRP-13628
Mar 23, 2028
BorenDiclofenac (as sodium)
25mg/mL Solution for Injection (I.M./I.V.)USP Type III Amber Glass Ampoule x 3mL (10 ampoules/plastic tray) Box of 10's & 100's
Rx
Reyoung Pharmaceutical Co. Ltd.China
Health Saver Pharma Inc.
DRP-2027
Jul 24, 2027
BorenDiclofenac Sodium
50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Centurion Laboratories Pvt. Ltd.India
Philgen Pharmaceuticals Inc.
DRP-18011
Dec 5, 2030
BorenDiclofenac Sodium
50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Centurion Remedies Pvt. Ltd.India
Philgen Pharmaceuticals Inc.
DRP-3882
May 25, 2029
CatafenDiclofenac Sodium
50 mg SuppositoryPVC/PE Film Strip x 5's (Box of 10's)
Rx
Bliss GVS Pharma Ltd.India
Endure Medical Inc.
DR-XY44207
Feb 13, 2030
CataflamDiclofenac potassium
25 mg Sugar-Coated TabletBlister Pack x 10’s (Box of 100’s); Blister Pack x 10’s (Box of 10’s) (as Physician’s Sample)
Rx
Novartis Saglik, Gida Ve Tarim Urunleri San. Ve Tic A.S.Turkey
Novartis Healthcare Philippines, Inc.
DRP-4018
Jan 18, 2031
CataflamDiclofenac Potassium
50 mg Sugar-Coated TabletPVC/PE/PVDC Blister pack x 10's Box of 100's; PVC/PE/PVDC Blister pack x 10's Box of 10's [as physician's sample]
Rx
Novartis Saglik, Gida ve Tarim Urunleri Sanayi ve Ticaret, A.S.Turkey
Novartis Healthcare Philippines, Inc.
DRP-7687
Feb 1, 2029
CataflinDiclofenac Potassium
50 mg Film-Coated TabletBlister Pack x 10's (Box of 100's)
Rx
—
Phil. Pharmawealth, Inc.
DR-XY34228
Jan 31, 2028
ClodifloxDiclofenac sodium
50 mg Rectal SuppositoryPVC/PE Blister Film x 5’s (Box of 100’s)
Rx
Farmaprim Ltd.Republic of Moldova
Ambica International Corporation
DRP-8967
Aug 17, 2037
ClofefarDiclofenac Sodium
100 mg Sustained-Release TabletAluminum Strip x 10’s (Box of 20's)
Rx
Agio Pharmaceuticals Ltd.India
JJYSRINN Trading Inc.Importer: Ambica International Corporation
DRP-978-01
May 19, 2030
ClofefarDiclofenac Sodium
50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
XL Laboratories Pvt. Ltd.India
JJYSRINN TRADING INC.Importer: Ambica International Corporation
DRP-2893-02
Mar 19, 2030
ClofenadDiclofenac Sodium
50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
SAPPHIRE LIFESCIENCES PVT. LTDIndia
777 Red Pharma IncImporter: NELPA LIFESCIENCES, INC.
DRP-5609-01
Oct 15, 2029
CLOFENADDiclofenac Sodium
50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s)
Rx
Genom Biotech Pvt. Ltd.India
777 Red Pharma Inc.Importer: Nelpa Lifesciences, Inc.
DRP-5609-02
Mar 24, 2031
Clofenex-50Diclofenac Sodium
50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
XL Laboratories Pvt. Ltd.India
Vispomed EnterprisesImporter: Ambica International Corporation
DRP-2893
Mar 19, 2030
ClofenovaDiclofenac Potassium
50 mg Film-Coated TabletAlu-Clear PVC Blister Pack x 10's (Box of 100's)
Rx
SAGA LIFESCIENCES LIMITEDIndia
GA2 Pharmaceutical Inc.Importer: MEDINOVA PHARMACEUTICAL INC.
DRP-8456-01
Nov 28, 2028
ClofepenDiclofenac (As Sodium)
50 mg Enteric-Coated TabletAlu/ PVC Blister Pack x 10's (Box of 100's)
Rx
S Kant Healthcare Ltd.India
Multigro Healthcare Inc.Importer: Grovic Pharma Inc.
DRP-5152-04
Dec 23, 2029
ClofezestDiclofenac Sodium
25 mg/mL (75 mg/ 3 mL) Solution for Injection (I.M./I.V.)USP Type I clear glass ampoule x 3 mL (Box of 5's)
Rx
East African (India) OverseasIndia
Ambica International Corporation
DRP-13008
Nov 16, 2027
ClogelDiclofenac (as Diethylamine)
10 mg/g (1% w/w) Topical GelAluminum tube x 20 g (Box of 1's)
OTC
Lloyd Laboratories, Inc.Philippines
TGP Pharma Inc.Trader: Euro-Health Care Exponents, Inc.
DR-XY35746
Apr 27, 2029
ClopichemDiclofenac sodium
50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
ChemEx Logistics and Trading Inc.Trader: Westfield Pharmaceuticals, Inc.
DRP-2652-04
Jun 4, 2027
CoxynDiclofenac sodium (equivalent to Diclofenac diethylamine)
10 mg/g (1%w/w) Topical GelAluminum collapsible tube x 30 g (Box of 1's)
Rx
Lincoln Pharmaceuticals Ltd.India
Despina Pharma Inc.
DRP-12834
Oct 12, 2027
CurafenDiclofenac Sodium
100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
The ACME Laboratories LimitedBangladesh
Euro Generics International Phils., Inc.
DRP-6386
Jan 7, 2028
DafenacDiclofenac Sodium
25 mg/mL (75 mg/3 mL) Solution for Injection (IM)USP Type I Clear Glass Ampoule x 3 mL (Box of 10's)
Rx
Gland Pharma LimitedIndia
Endure Medical, Inc.
DR-XY35969
Jun 8, 2029
DefnacDiclofenac Sodium
25 mg/ mL Solution for InjectionUSP Type I Amber Glass Ampoule x 3 mL (Box of 5’s)
Rx
The Searle Company LimitedPakistan
Ambica International Corporation
DR-XY40922
Jun 15, 2030
DiclaustinDiclofenac Sodium
50 mg Enteric-Coated TabletBlister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Paramed Pharmaceuticals, Inc.Trader: Eadriex Pharmaceuticals Phils., Inc
DRP-2257-01
Feb 19, 2027
DiclocareDiclofenac Sodium
25 mg/mL (75 mg/3 mL) Solution for Injection (IM/IV)3 mL USP Type Amber Glass Ampoule (Box of 10's)
Rx
Furen Pharmaceutical Group Co., Ltd.China
Bellus Life Solutions, Inc.Importer: Aglobal Care, Inc.
DRP-9040-01
Oct 24, 2031
DiclofamDiclofenac sodium
50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's Box of 100's
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Westfield Pharmaceuticals, Inc.
DRP-2652
Jun 4, 2027
Diclofen-50Diclofenac Sodium
50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Centurion Laboratories Pvt. Ltd.India
TGP Pharma Inc.Importer: Philgen Pharmaceuticals Inc.
DRP-17382-01
Dec 5, 2030
Diclofen-50Diclofenac Sodium
50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Centurion Remedies Pvt. Ltd.India
TGP Pharma Inc.Importer: Philgen Pharmaceuticals Inc.
DRP-3882-01
May 25, 2029
DiclogenDiclofenac Sodium
100 mg Sustained-Release TabletAluminum Strip x 10’s Box of 20’s and 100’s
Rx
Agio Pharmaceuticals Ltd.India
Ambica International Corporation
DRP-978
May 19, 2030
DiclogenDiclofenac Sodium
25 mg/mL (75 mg/3 mL) Solution for Injection (I.M.)Type I Clear Colorless Glass Ampoule x 3 mL (Box of 5's)
Rx
Agio Pharmaceuticals Ltd.India
Ambica International Corporation
DRP-5697
Nov 7, 2030
Diclollen-GE100Diclofenac sodium
100 mg Sustained-Release TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Genom Biotech Pvt. Ltd.India
Ollen Pharma Trading Inc.
DRP-17852
Mar 25, 2031
DiclominDiclofenac (as Sodium)
50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
S Kant Healthcare Ltd.India
Neos-King Pharma Inc.Importer: Grovic Pharma Inc.
DRP-5152-02
Dec 23, 2029
DiclonacDiclofenac Sodium
50 mg Enteric Coated TabletBlister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Altomed Pharmaceuticals, Inc.Trader: Interhealthcare Pharmaceuticals, Inc.
DRP-2193-01
Aug 28, 2027
DiclophilDiclofenac (as sodium)
25mg/mL (75mg/3mL) Solution for Injection (I.M./I.V.)Amber Glass Ampoule x 3 mL (Box of 10's)
Rx
CSPC Ouyi Pharmaceutical Co. Ltd.China
AMB HK Enterprises Inc.
DRP-12104
Jun 13, 2027
DiclophilDiclofenac sodium
25mg/mL Solution for Injection (IM/IV)Type I Clear Glass Ampoule with Blue dot x 3mL in PVC Tray (Box of 10's)
Rx
Ratnatris Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises, Inc.
DRP-17324
Nov 14, 2030
Dicloran GelDiclofenac Sodium
10 mg/g (1% w/w) Topical GelLacquer Coated Aluminum Collapsible Tube x 20 g (Box of 1’s)
Rx
Unique Pharmaceuticals Laboratories (A Division of J.B. Chemicals & Pharmaceuticals Ltd.)India
JBCPL Philippines Inc.
DRP-4169
Jan 3, 2028
DiclosafeDiclofenac Sodium
100 mg Rectal SuppositoryWhite PVC/PE strip of 5's (Box of 10's)
Rx
Kusum Healthcare Pvt. Ltd. (Block II)India
Kusum Healthcare Private Limited Branch Office
DR-XY48209
Jul 21, 2027
DiclosafeDiclofenac sodium
50 mg Rectal SuppositoryPVC/PE Strip x 5's (Box of 10's)
Rx
Kusum Healthcare Pvt. Ltd. (Block III)India
Kusum Healthcare Private Limited Branch Office
DR-XY46946
Aug 17, 2030
DiclosaphDiclofenac Sodium
25mg/mL Solution For Injection (IM/IV)USP Type I flint glass ampoule x 3 mL (Box of 5 ampoules in white plastic tray)
Rx
Kilitch Drugs (I) Ltd.India
Nelpa Lifesciences, Inc.
DRP-11194
Feb 11, 2027
DicloseaDiclofenac (as sodium)
50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
S Kant Healthcare Ltd.India
SEA-King Pharma Inc.Importer: Grovic Pharma Inc.
DRP-5152-03
Dec 23, 2029
DiclotrueDiclofenac Sodium
25 mg/ mL Solution for Injection (IM/IV)USP Type I glass ampoule x 3 mL (Box of 10 ampoules in a plastic tray)
Rx
Cooper Pharma LimitedIndia
Ambica International Corporation
DRP-12487
Aug 18, 2027
DicloxDiclofenac Sodium
50 mg Enteric-Coated TabletBlister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
999 Seth Pharmaceutical Inc.Trader: Interhealthcare Pharmaceuticals, Inc.
DRP-2193
Aug 28, 2027
DicloxiriDiclofenac Sodium
25 mg/mL (75 mg/ 3 mL) Solution for Injection (I.M./I.V.)USP Type I amber coloured glass ampoule x 3 mL
Rx
Pharmax India Private LimitedIndia
Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd.
DRP-13007
Nov 16, 2027
DiclozedDiclofenac sodium
25 mg/mL Solution for Injection (IM/IV)Clear Glass Ampoule x 5 mL (Box of 10's)
Rx
Sakar Healthcare Pvt. Ltd.India
Macropharma Corporation
DRP-10854
Dec 9, 2031
DicofenDiclofenac Sodium
25 mg/mL Solution for Injection (IM/IV)3 mL USP Type I Amber Glass Ampoule with Red and Blue Ring (Box of 10's)
Rx
Furen Pharmaceutical Group Co., Ltd.China
Endure Medical Inc.
DR-XY44146
Feb 11, 2030
DictasDiclofenac Sodium
50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10’s Box of 100’s
Rx
Umedica Laboratories Pvt. Ltd.India
Suhitas Pharmaceuticals Inc.
DRP-8220
Mar 18, 2029
DifenaminDiclofenac Sodium
50 mg Enteric-Coated TabletBlister Pack x 10's (Box of 100's)
Rx
Flamingo Pharmaceuticals Ltd.India
Hexagon Pharmaceuticals
DRP-545
May 13, 2027
Difenax (reformulated)Diclofenac Sodium
50 mg Enteric-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: GX International, Inc.
DR-XY33250
Aug 1, 2028
DiflacDiclofenac Potassium
50 mg Film-Coated TabletAlu-Clear PVC blister pack by 10’s Box of 100’s
Rx
SAGA LIFESCIENCES LIMITEDIndia
MEDINOVA PHARMACEUTICAL INC.
DRP-8456
Nov 28, 2028
DiflonaxDiclofenac (as sodium)
25 mg/mL Solution for Injection (IM/IV)Type I glass ampoule packed in tray x 3 mL (Box of 10's)
Rx
Psychotropics India Limited (General Block)India
Despina Pharma Inc.
DRP-15594
Aug 14, 2029
DiflosidDiclofenac (as sodium)
25 mg/mL Solution for Injection (IM/IV)USP Type I Glass Ampoule x 3 mL in 2 Plastic Trays x 5's Box of 10's
Rx
Geofman PharmaceuticalsPakistan
Sahar International Trading Inc.
DRP-6689
Jul 30, 2029
DiklonacDiclofenac
10 mg/g (1% w/w) GelAluminum Collapsile Tube x 30 g (Box of 1's)
OTC
S Kant Healthcare LimitedIndia
Aglobal Care, Inc.
DRP-12755
Oct 6, 2027
DitionDiclofenac Sodium
1 g (equivalent to Diclofenac Diethylamine) (1% w/w) per 100g Topical Gel Topical GelAluminum Tube x 20 g (Box of 1's)
OTC
S Kant Healthcare LimitedIndia
Suhitas Pharmaceuticals Inc.
DRP-10798
Nov 25, 2026
DolfenDiclofenac Sodium
25 mg/mL (75 mg/3mL) Solution for Injection (I.M./I.V.)USP Type I Clear Glass Ampoule x 3 mL (Box of 10's)
Rx
Swiss Parenterals, Ltd.India
Endure Medical, Inc.
DR-XY41180
Aug 28, 2027
DosanacDiclofenac Sodium
25 mg/mL Solution for Injection (IM)Clear/Colorless Glass Ampoule in a blister tray x 10's (Box of 50's)
Rx
T.P. Drug Laboratories (1969) Co., Ltd.Thailand
Lordla Pharma Sales
DRP-707
Mar 2, 2029
DycloDiclofenac Sodium
25 mg/mL Solution For Injection (IM/IV)USP Type I Amber Glass Ampoule x 3 mL (Box of 4 Alu/PVC blister packs x 5 ampoules)
Rx
Indus Pharma (Pvt.) Ltd.Pakistan
One Dexcel Pharma Inc.
DRP-11899
May 18, 2027
DyflarenDiclofenac (as sodium)
25 mg/mL (75 mg/3 mL) Solution for Injection3 mL USP Type I Clear Colorless Glass Ampoule (Box of 10’s in a plastic tray)
Rx
Venus InternationalIndia
AGB Pharmaceutical Trading and Consultancy Corp.Importer: Ambica International Corporation
DRP-4174-01
Nov 27, 2028
Dynapar-ECDiclofenac (as sodium)
50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Troikaa Pharmaceuticals LimitedIndia
Troikaa Pharmaceuticals Philippines, Inc.
DR-XY42654
Sep 17, 2028
Dynapar-SR 100Diclofenac (as sodium)
100mg Sustained Release TabletAlu/PVC Blister Pack x 10's ( Box of 100's)
Rx
Troikaa Pharmaceuticals LimitedIndia
Troikaa Pharmaceuticals Philippines, Inc.
DR-XY42541
Jan 3, 2029
ErdonDiclofenac Sodium( as diethylamine)
10 mg/g (1% w/w) Gel10 g Aluminum Collapsible tube Box of 1's
Rx
Aristopharma LtdBangladesh
Sahar International Trading Inc
DR-XY45469
Jun 30, 2031
F-DicloDiclofenac Sodium
25 mg/mL (75 mg/3 mL) Solution for Injection (IM/IV)3 mL USP Type Amber Glass Ampoule (Box of 10's)
Rx
Furen Pharmaceutical Group Co., Ltd.China
Aglobal Care Inc.
DRP-9040
Sep 24, 2030
FencidDiclofenac Sodium
50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Reta DrugTrader: Westfield Pharmaceuticals, Inc.
DRP-2652-02
Jun 4, 2027
FlexgelDiclofenac (as diethylamine)
10mg/g (1%w/w)Topical Gel25 g Aluminum Collapsible Tube in a Box
Rx
The United Drug (1996) Co., Ltd.Thailand
Endure Medical, Inc.Importer: Singapore Genebio, Inc.
DR-XY41463
Dec 12, 2027
Globanac 50Diclofenac Sodium
50 mg Enteric-Coated TabletAlu/ Clear PVC Blister pack x 10’s (Box of 100's)
Rx
AKRITI PHARMACEUTICALS PVT. LTD.India
AGLOBAL CARE, INC.Trader: PPJ PHARMA PVT. LTD.
DRP-8107
Jun 6, 2027
GofenacDiclofenac Sodium
25 mg/mL (75 mg/3 mL) Solution for Injection (I.M.)Type I Clear Colorless Glass Ampoule x 3 mL (Box of 5's)
Rx
Agio Pharmaceuticals Ltd.India
Applied Pharmaceutical Distribution IncImporter: Ambica International Corporation
DRP-5697-01
Nov 7, 2030
Healthcare Joint PainDiclofenac Sodium
50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 20's)
Rx
Lloyd Laboratories, Inc.Philippines
—
DR-XY39262 (For Export Only)
Apr 5, 2030
LofenaxDiclofenac Sodium
25 mg/mL Solution for InjectionUSP Type I Amber Glass Ampoule 3 mL (Box of 10's)
Rx
Geofman PharmaceuticalsPakistan
Clinbaxy International, Inc.
DR-XY30144
Oct 15, 2027
LufenacDiclofenac Sodium
50 mg Enteric-Coated TabletAlu/ Clear PVC Blister pack X 10’s (Box of 100’S)
Rx
Akriti Pharmaceuticals Pvt. Ltd.India
BELLUS LIFE SOLUTIONS, INC.Importer: AGLOBAL CARE, INC.Trader: PPJ PHARMA PVT. LTD.
DRP-8107-01
Jun 6, 2027
MedclofDiclofenac sodium
25 mg/mL Solution for Injection (IM/IV)USP Type I Amber Glass Ampoule x 3 mL (In Blister Pack x 5’s) (Box of 10’s)
Rx
Samjin Pharmaceutical Co., Ltd.Republic of Korea
Nutramedica Inc.Importer: Medbridge, Inc.
DR-XY34034
Dec 6, 2030
MesofidDiclofenac Sodium
50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's Box of 100's
Rx
Lloyd Laboratories, Inc.Philippines
MeedPharma Medical Supplies & Equipment DistributorTrader: Westfield Pharmaceutical, Inc.
DRP-2652-01
Jun 4, 2027
MinefenacDiclofenac Sodium
25mg/mL (75mg/3mL) Solution For Injection (IM/IV)USP Type I Clear/Colourless Glass Ampoule x 3 mL (Box of 10's)
Rx
Makcur Laboratories LimitedIndia
Diafarm Inc.
DRP-17313
Nov 13, 2030
MioclofDiclofenac (as sodium)
25 mg/mL (75 mg/3 mL) Solution for Injection3 mL USP Type I Clear Colorless Glass Ampoule (Box of 10’s in a plastic tray)
Rx
Venus InternationalIndia
Ambica International Corporation
DRP-4174
Nov 27, 2028
MuscortexDiclofenac sodium
50 mg TabletBlister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Foramen Products Corporation
DR-XY31415
Apr 4, 2030
Neo-PyrazonDiclofenac Sodium
50 mg Enteric Film-Coated TabletAluminum Flex Foil x 4's (Box of 100's)
Rx
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DRP-2612
Jun 25, 2028
NoneDiclofenac Sodium
50 mg Enteric Film-Coated TabletAluminum Flex Foil x 4's (Box of 100's)
Rx
Amherst Laboratories, Inc.Philippines
RiteMED Phils., Inc.Trader: UNILAB, Inc.
DRP-2612-02
Jun 25, 2028
NoneDiclofenac Sodium
50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Watsons Personal Care Stores (Philippines), Inc.Trader: Westfield Pharmaceuticals, Inc.
DRP-2652-03
Jun 4, 2027
NoneDiclofenac Sodium
50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
XL Laboratories Pvt. Ltd.India
ATC Healthcare International Corp.Importer: Ambica International Corporation
DRP-2893-03
Mar 19, 2030
NoneDiclofenac (As Sodium)
50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's Box of 100's
Rx
S KANT HEALTHCARE LTD.India
ACTIMED, INC.Importer: GROVIC PHARMA INC.
DRP-5152
Dec 23, 2029
NovanacDiclofenac Sodium
25mg/mL (75mg/3mL) Solution For Injection (IM/IV)3 mL USP Type I amber glass ampoule
Rx
Bharat Parenterals, LimitedIndia
Medinova Pharmaceutical Inc.
DRP-19087
Oct 27, 2031
PhenylacDiclofenac Sodium
25 mg/mL Solution For Injection (I.M./I.V.)3 mL USP Type I glass ampoule in PVC tray (Box of 5's)
Rx
Hebei Tiancheng Pharmaceutical Co., Ltd.China
PhilRx Pharma Inc.
DRP-13305
Jan 23, 2028
Philflam DRDiclofenac Sodium
50 mg Delayed-Release TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s)
Rx
Jiangxi Xierkangtai Pharmaceutical Co., Ltd.China
PhilRx Pharma Inc.
DRP-7975
Mar 16, 2031
QuickierDiclofenac
10 mg/g (1% w/w) (equivalent to 11.6 mg Diclofenac Diethylamine) Topical GelLaminated Tube x 10 g and 20 g (Box of 1's)
OTC
Fredun Pharmaceuticals Ltd.India
AMB HK Enterprises Inc.
DRP-11869
May 12, 2027
RheudiDiclofenac (as Sodium)
50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Philippine Home Pharmaceuticals
DR-XY33750
Aug 22, 2027
RheuflamDiclofenac Sodium
25 mg/mL (75 mg/3 mL) Solution for Injection (IM)Amber Glass Ampoule x 3 mL (Box of 10's)
Rx
STANDARD CHEM. & PHARM. CO., LTD.Taiwan
PHIL. PHARMAWEALTH, INC.
DR-XY23782
Jan 23, 2028
RinefenDiclofenac Sodium
50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10’s Box of 100’s
Rx
Umedica Laboratories Pvt. Ltd.India
Jjysrinn Trading Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-8220-01
Mar 18, 2029
SaphlocidDiclofenac Sodium
50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-5609
Mar 24, 2031
SitiflamDiclofenac Sodium
50mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 20's and 100's)
Rx
Hubei Huazhong Pharmaceutical Co., Ltd.China
SAHAR INSahar International Trading, Inc.TERNATIONAL TRADING INC.Importer: Sahar International Trading, Inc.
DR-XY41561
Jan 3, 2028
Subsyde-CRDiclofenac Sodium
100 mg Controlled-Release CapsuleBlister Strip x 10's Box of 100's
Rx
Raptakos, Brett & Co. Ltd.India
Raptakos, Brett & Co. Ltd.
DRP-1727
Aug 12, 2027
TrifocidDiclofenac Sodium
50 mg Enteric-Coated TabletBlister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Rilem Pharma Corp.Trader: Eadriex Pharmaceuticals Phils., Inc.
DRP-2257
Feb 19, 2027
UnbrandedDiclofenac Sodium
25 mg Enteric Coated TabletAlu/Clear PVC Blister Pack x 20's Box of 100's
Rx
Drugmaker’s Laboratories Inc.Philippines
—
DRP-8062
Jun 23, 2029
UnbrandedDiclofenac Sodium
50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
XL Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Diafarm Inc.
DRP-2893-01
Mar 19, 2030
Vantelin GelDiclofenac Sodium
10 mg (1% w/w) per g Topical GelAluminum Tube x 20 g & 45 g (Box of 1's)
OTC
Y.S.P. Industries (M) SDN. BHDMalaysia
DKSH Market Expansion Services Philippines, Inc.
DR-XY49364
Mar 25, 2030
VindicloDiclofenac Sodium
50 mg Enteric-Coated TabletBlister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Vincare PharmaTrader: Eadriex Pharmaceuticals Phils., Inc.
DRP-2257-02
Feb 19, 2027
VodefenDiclofenac Potassium
50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Mercury Laboratories Ltd.India
Phil Pharmawealth, Inc.
DR-XY38791
Nov 25, 2030
VoltarenDiclofenac Sodium
25 mg Enteric Coated TabletPVC/PE/PVDC (Triplex) Blister Pack backed with a heat-sealable lacquered aluminum foil x 10’s (Box of 100's); PVC/PE/PVDC (Triplex) Blister Pack backed with a heat-sealable lacquered aluminum foil x 10’s (Box of 10's, as Physician's Sample)
Rx
Novartis Saglik, Gida Ve Tarim Urunleri San. Ve Tic. A.S.Turkey
Importer: Novartis Healthcare Philippines, Inc.
DR-XY28428
Mar 19, 2028
VoltarenDiclofenac Sodium
25 mg/mL Solution for Injection (IM/IV)Colorless Glass Ampoule x 3 mL Box of 10's
Rx
Lek Pharmaceuticals D.D.Slovenia
Importer: Novartis Healthcare Philippines, Inc.
DR-X1740
Aug 20, 2027
Voltaren EmulgelDiclofenac (as diethylamine)
1 g/100 g (1%) EmulgelAluminum Tube with HDPE Screw Cap x 5 g and 20 g (Box of 1's)
OTC
GlaxoSmithKline Consumer Health Care Pakistan LimitedPakistan
Importer: GlaxoSmithKline Consumer Healthcare Philippines, Inc.
DR-XY27796
Aug 29, 2027
Voltaren Emulgel 12 HoursDiclofenac
18.6mg/g (1.86% w/w) Topical GelAluminum Laminated Tube x 30g (Box of l’s
OTC
GSK Consumer Healthcare S.A.Switzerland
Importer: Glaxosmithkline Consumer Healthcare Philippines, Inc.
DR-XY47470
Nov 16, 2026Past listed date
Voltaren ForteDiclofenac sodium
50 mg Enteric-Coated TabletAlu/PVC/PE/PVDC Blister Pack x 10’s (Box of 100's)
Rx
Novartis Saglik, Gida Ve Tarim Urunleri San. Ve Tic. A.S.Turkey
Novartis Healthcare Philippines, Inc.
DR-XY27769
Aug 19, 2027
Voltaren SRDiclofenac Sodium
100 mg Sustained-Release Film-Coated TabletPVC/PE/PVDC Blister Pack x 10's (Box of 10's and 100's)
Rx
Novartis Farma S.P.A.Italy
Importer: Novartis Healthcare Philippines, Inc.
DR-XY27795
Apr 30, 2029
VorenDiclofenac Sodium
10 mg/g (1% w/w) GelAluminum Tube x 20 g Box of 1's
Rx
Y.S.P Industries (M) Sdn. Bhd.Malaysia
Yung Shin (Philippines),Inc.
DR-XY16632
Oct 13, 2029
VorenDiclofenac Sodium
12.5 mg Rectal SuppositoryGreen-Colored PVC-Based Peel-Off Strip x 10's (Box of 100's)
Rx
Y.S.P. Industries (M) Sdn. Bhd.Malaysia
Yung Shin (Philippines), Inc.
DR-XY47668
Jan 18, 2027
VorenDiclofenac sodium
25 mg Rectal SuppositoryBlue-Colored PVC-Based Peel-Off Strip x 10's (Box of 100's)
Rx
Y.S.P. Industries (M) Sdn. Bhd.Malaysia
Yung Shin (Philippines), Inc.
DR-XY47669
Jan 18, 2032
VorenDiclofenac Sodium
25 mg/mL Solution for Injection (I.M.)Clear and Colorless Glass Ampoule x 3 mL (Box of 10's)
Rx
Yung Shin Pharm. Ind. Co., Ltd.Taiwan
Yung Shin (Philippines), Inc.
DR-XY12275
Sep 17, 2029
VorenDiclofenac sodium
50 mg Enteric-Coated TabletBlister Pack x 10's (Box of 100's)
Rx
Y.S.P. Industries (M) Sdn. Bhd.Malaysia
Philgen Pharmaceuticals Inc.
DR-XY25662
Nov 10, 2029
VorenDiclofenac sodium
50 mg Rectal SuppositoryRed-Colored PVC-Based Peel-Off Strip x 10's (Box of 100's)
Rx
Y.S.P. Industries (M) Sdn. Bhd.Malaysia
Yung Shin (Philippines), Inc.
DR-XY47667
Jan 18, 2032
Voren ForteDiclofenac Sodium
50 mg CapsuleBlister Pack x 10's (Box of 100's)
Rx
Yung Shin Pharm. Ind. Co. Ltd.-Taichung Youth FactoryTaiwan
Yung Shin (Philippines),Inc.
DR-XY17218-B
Oct 21, 2029
VovenilDiclofenac (as Sodium)
25mg/mL Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 3 mL (Box of 5 ampoules x 3 mL)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant III Injectables)India
Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-13141
Dec 7, 2027
ZobidDiclofenac Sodium
25 mg/mL Solution for Injection (IM)3 mL USP Type I Clear Glass Ampoule x 10's in plastic tray per box
Rx
SM Pharmaceutical (M) Sdn. Bhd.Malaysia
Importer: PNF Pharmaceutical, Inc.
DRP-8321
Apr 14, 2028
ZolterolDiclofenac Sodium
100 mg Sustained Release TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 100's)
Rx
Upha Pharmaceutical Mfg (M) Sdn BhdMalaysia
CCM International (Philippines), Inc.Trader: CCM Pharmaceuticals Sdn. Bhd.
DR-XY40513
Jan 10, 2027
(no brand name)Diclofenac (as diethylamine)
10 mg/g (1% w/w) Topical GelLaminated Tube x 30 g (Box of 1's)
Rx
Rhydburg Pharmaceuticals Ltd.India
Khriz Pharma Trading Inc.
DRP-12105
Jun 13, 2027
(no brand name)Diclofenac Sodium
10 mg/g (equivalent to 11.6 mg/g (1.16% w/w) Diclofenac Diethylamine) Topical GelLaminated Tube with Cap x 30 g (Box of 1’s)
OTC
Rhydburg Pharmaceuticals Ltd.India
Genedrift Philippines OPC
DRP-17925
Apr 30, 2031
(no brand name)Diclofenac Potassium
50 mg Granules for Oral SolutionAluminum Flex Foil Sachet x 1.2 g (Box of 100 W Sachets)
Rx
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DRP-10871
Dec 9, 2026

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label

WARNINGS Cardiovascular Thrombotic Events Clinical trials of several COX-2 selective and nonselective NSAIDs of up to 3 years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI), and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs.

The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate.

Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses. To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible.

Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur. There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use.

The concurrent use of aspirin and an NSAID, such as diclofenac, increases the risk of serious gastrointestinal (GI) events (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation). Status Post Coronary Artery Bypass Graft (CABG) Surgery Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.

NSAIDs are contraindicated in the setting of CABG (see CONTRAINDICATIONS). Post-MI Patients Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment.

In this same cohort, the incidence of death in the first year post-MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up.

Avoid the use of diclofenac sodium delayed-release tablets in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If diclofenac sodium delayed-release tablets is used in patients with a recent MI, monitor patients for signs of cardiac ischemia. Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs, including diclofenac, can cause serious gastrointestinal (GI) adverse events, including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.

These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy, is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3 - 6 months, and in about 2% - 4% of patients treated for one year.

However, even short-term therapy is not without risk. Risk Factors for GI Bleeding, Ulceration, and Perforation Patients with a prior history of peptic ulcer disease and/or GI bleeding who use NSAIDs had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors. Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking, use of alcohol, older age, and poor general health status.

Most postmarketing reports of fatal GI events occurred in elderly or debilitated patients. Additionally, patients with advanced liver disease and/or coagulopathy are at increased risk for GI bleeding. Strategies to Minimize the GI Risks in NSAID-treated patients Use the lowest effective dosage for the shortest possible duration.

Avoid administration of more than one NSAID at a time Avoid use in patients at higher risk unless benefits are expected to outweigh the increased risk of bleeding. For such patients, as well as those with active GI bleeding, consider alternate therapies other than NSAIDs. Remain alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy.

If a serious GI adverse event is suspected, promptly initiate evaluation and treatment, and discontinue diclofenac sodium delayed-release tablets until a serious GI adverse event is ruled out. In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, monitor patients more closely for evidence of GI bleeding (see PRECAUTIONS; Drug Interactions).

Hepatotoxicity In clinical trials of diclofenac-containing products, meaningful elevations (i.e., more than 3 times the upper limit of normal [ULN]) of aspartate aminotransferase (AST) (also known as SGOT) were observed in about 2% of approximately 5700 patients at some time during diclofenac treatment (alanine aminotransferase [ALT] was not measured in all studies). In a large, open-label, controlled trial of 3700 patients treated with oral diclofenac sodium for 2 to 6 months, patients were monitored first at 8 weeks and 1200 patients were monitored again at 24 weeks.

Meaningful elevations of ALT and/or AST occurred in about 4% of patients and included marked elevations (greater than 8 times the ULN) in about 1% of the 3700 patients. In that open-label study, a higher incidence of borderline (less than 3 times the ULN), moderate (3 to 8 times the ULN), and marked (greater than 8 times the ULN) elevations of ALT or AST was observed in patients receiving diclofenac when compared to other NSAIDs.

Elevations in transaminases were seen more frequently in patients with osteoarthritis than in those with rheumatoid arthritis. Almost all meaningful elevations in transaminases were detected before patients became symptomatic. Abnormal tests occurred during the first 2 months of therapy with diclofenac in 42 of the 51 patients in all trials who developed marked transaminase elevations.

In postmarketing reports, cases of drug-induced hepatotoxicity have been reported in the first month, and in some cases, the first 2 months of therapy, but can occur at any time during treatment with diclofenac. Postmarketing surveillance has reported cases of severe hepatic reactions, including liver necrosis, jaundice, fulminant hepatitis with and without jaundice, and liver failure.

Some of these reported cases resulted in fatalities or liver transplantation. In a European retrospective population-based, case-controlled study, 10 cases of diclofenac associated drug- induced liver injury with current use compared with non-use of diclofenac were associated with a statistically significant 4-fold adjusted odds ratio of liver injury.

In this particular study, based on an overall number of 10 cases of liver injury associated with diclofenac, the adjusted odds ratio increased further with female gender, doses of 150 mg or more, and duration of use for more than 90 days. Physicians should measure transaminases at baseline and periodically in patients receiving long-term therapy with diclofenac, because severe hepatotoxicity may develop without a prodrome of distinguishing symptoms.

The optimum times for making the first and subsequent transaminase measurements are not known. Based on clinical trial data and postmarketing experiences, transaminases should be monitored within 4 to 8 weeks after initiating treatment with diclofenac. However, severe hepatic reactions can occur at any time during treatment with diclofenac.

If abnormal liver tests persist or worsen, if clinical signs and/or symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, abdominal pain, diarrhea, dark urine, etc.), diclofenac sodium delayed-release tablets should be discontinued immediately. Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms).

If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), discontinue diclofenac sodium delayed-release tablets immediately, and perform a clinical evaluation of the patient. To minimize the potential risk for an adverse liver related event in patients treated with diclofenac sodium delayed-release tablets, use the lowest effective dose for the shortest duration possible.

Exercise caution when prescribing diclofenac sodium delayed-release tablets with concomitant drugs that are known to be potentially hepatotoxic (e.g., acetaminophen, antibiotics, anti- epileptics). Hypertension NSAIDs, including diclofenac sodium delayed-release tablets, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events.

Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazides diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs (see PRECAUTIONS; Drug Interactions). Monitor blood pressure (BP) during the initiation of NSAID treatment and throughout the course of therapy. Heart Failure and Edema The Coxib and traditional NSAID Trialists’ Collaboration meta-analysis of randomized controlled trials demonstrated an approximately 2-fold increase in hospitalization for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients.

In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death. Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of diclofenac may blunt the CV effects of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]) (see PRECAUTIONS; Drug Interactions).

Avoid the use of diclofenac sodium delayed-release tablets in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If diclofenac sodium delayed-release tablets is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.

Renal Toxicity and Hyperkalemia Renal Toxicity Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.

Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. No information is available from controlled clinical studies regarding the use of diclofenac sodium delayed-release tablets in patients with advanced renal disease.

The renal effects of diclofenac sodium delayed-release tablets may hasten the progression of renal dysfunction in patients with preexisting renal disease. Correct volume status in dehydrated or hypovolemic patients prior to initiating diclofenac sodium delayed-release tablets. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of diclofenac sodium delayed-release tablets (see PRECAUTIONS; Drug Interactions).

Avoid the use of diclofenac sodium delayed-release tablets in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If diclofenac sodium delayed-release tablets is used in patients with advanced renal disease, monitor patients for signs of worsening renal function.

Hyperkalemia Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state. Anaphylactic Reactions Diclofenac has been associated with anaphylactic reactions in patients with and without known hypersensitivity to diclofenac and in patients with aspirin-sensitive asthma (see CONTRAINDICATIONS, WARNINGS; Exacerbation of Asthma Related to Aspirin Sensitivity).

Exacerbation of Asthma Related to Aspirin Sensitivity A subpopulation of patients with asthma may have aspirin-sensitive asthma, which may include chronic rhinosinusitis complicated by nasal polyps; severe, potentially fatal bronchospasm; and/or intolerance to aspirin and other NSAIDs. Because cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, diclofenac sodium delayed-release tablets is contraindicated in patients with this form of aspirin sensitivity (see CONTRAINDICATIONS).

When diclofenac sodium delayed-release tablets is used in patients with preexisting asthma (without known aspirin sensitivity), monitor patients for changes in the signs and symptoms of asthma. Serious Skin Reactions NSAIDs, including diclofenac, can cause serious skin adverse reactions, such as exfoliative dermatitis, Stevens- Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal.

These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin reactions and to discontinue the use of diclofenac sodium delayed-release tablets at the first appearance of skin rash or any other sign of hypersensitivity. Diclofenac sodium delayed-release tablets is contraindicated in patients with previous serious skin reactions to NSAIDs (see CONTRAINDICATIONS).

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs, such as diclofenac sodium delayed-release tablets. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling.

Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved.

It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue diclofenac sodium delayed-release tablets and evaluate the patient immediately. Fetal Toxicity Premature Closure of Fetal Ductus Arteriosus Avoid use of NSAIDs, including diclofenac sodium delayed-release tablets, in pregnant women at about 30-weeks’ gestation and later.

NSAIDs, including diclofenac sodium delayed-release tablets, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age. Oligohydramnios/Neonatal Renal Impairment Use of NSAIDs, including diclofenac sodium delayed-release tablets, at about 20-weeks’ gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment.

These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation.

In some postmarketing cases of impaired neonatal renal function, invasive procedures, such as exchange transfusion or dialysis were required. If NSAID treatment is necessary between about 20 weeks and 30-weeks’ gestation, limit diclofenac sodium delayed-release tablets use to the lowest effective dose and shortest duration possible.

Consider ultrasound monitoring of amniotic fluid if diclofenac sodium delayed-release tablets treatment extends beyond 48 hours. Discontinue diclofenac sodium delayed-release tablets if oligohydramnios occurs and follow up according to clinical practice (see PRECAUTIONS; Pregnancy). Hematologic Toxicity Anemia has occurred in NSAID-treated patients.

This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient treated with diclofenac sodium delayed-release tablets, has any signs or symptoms of anemia, monitor hemoglobin or hematocrit. NSAIDs, including diclofenac sodium delayed-release tablets, may increase the risk of bleeding events.

Co-morbid conditions, such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding (see PRECAUTIONS; Drug Interactions).

Drug interactions

Drug or classSeverityEffectWhat to do
ACE inhibitors, ARBs, diuretics ("triple whammy")Adjust or monitorLess blood-pressure and diuretic effect; risk of acute kidney injury and hyperkalemia, especially in older, volume-depleted or CKD patients (label).Avoid the triple combination where possible; if used, check creatinine and potassium within 1 to 2 weeks and keep the patient hydrated.
Anticoagulants, antiplatelets (including aspirin), SSRIs, SNRIsAdjust or monitorHigher risk of serious bleeding (label).Avoid if possible; otherwise monitor for bleeding.
Other NSAIDs or salicylatesAvoidMore gastrointestinal toxicity without added benefit (label).Do not combine.
Lithium, methotrexate, cyclosporine, digoxinAdjust or monitorHigher levels or more nephrotoxicity (NSAID class labeling; not in the stored extract of this label).Monitor drug levels and kidney function.
Strong CYP2C9 inhibitors (e.g., voriconazole)Adjust or monitorHigher diclofenac exposure (label).Consider a lower diclofenac dose (AUC up 78% with voriconazole; label).

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

The formation of 4’- hydroxy- diclofenac is primarily mediated by CYP2C9.

Acyl glucuronidation mediated by UGT2B7 and oxidation mediated by CYP2C8 may also play a role in diclofenac metabolism.

CYP3A4 is responsible for the formation of minor metabolites, 5-hydroxy- and 3’-hydroxy-diclofenac.

Drug Interactions Studies Voriconazole: When coadministered with voriconazole (inhibitor of CYP2C9, 2C19, and 3A4 enzyme), the C max and AUC of diclofenac increased by 114% and 78%, respectively (see PRECAUTIONS;

Adverse reactions

Common

  • Abdominal pain, dyspepsia, nausea, diarrhea, constipation, flatulence
  • Headache, dizziness
  • Edema, elevated liver enzymes, rash, tinnitus

Serious

  • Cardiovascular thrombotic events (boxed warning)
  • Gastrointestinal bleeding, ulceration, perforation (boxed warning)
  • Acute kidney injury, papillary necrosis, hyperkalemia
  • Heart failure and edema; hypertension
  • Hepatotoxicity
  • Serious skin reactions, DRESS, anaphylaxis
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label

ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: Cardiovascular Thrombotic Events (see WARNINGS) GI Bleeding, Ulceration and Perforation (see WARNINGS) Hepatotoxicity (see WARNINGS) Hypertension (see WARNINGS) Heart Failure and Edema (see WARNINGS) Renal Toxicity and Hyperkalemia (see WARNINGS) Anaphylactic Reactions (see WARNINGS) Serious Skin Reactions (see WARNINGS) Hematologic Toxicity (see WARNINGS) Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In patients taking diclofenac sodium delayed-release tablets, or other NSAIDs, the most frequently reported adverse experiences occurring in approximately 1% - 10% of patients are: Gastrointestinal experiences including: abdominal pain, constipation, diarrhea, dyspepsia, flatulence, gross bleeding/perforation, heartburn, nausea, GI ulcers (gastric/duodenal) and vomiting.

Abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritus, rashes, and tinnitus. Additional adverse experiences reported occasionally include: Body as a Whole: fever, infection, sepsis Cardiovascular System: congestive heart failure, hypertension, tachycardia, syncope Digestive System: dry mouth, esophagitis, gastric/peptic ulcers, gastritis, gastrointestinal bleeding, glossitis, hematemesis, hepatitis, jaundice Hemic and Lymphatic System: ecchymosis, eosinophilia, leukopenia, melena, purpura, rectal bleeding, stomatitis, thrombocytopenia Metabolic and Nutritional: weight changes Nervous System: anxiety, asthenia, confusion, depression, dream abnormalities, drowsiness, insomnia, malaise, nervousness, paresthesia, somnolence, tremors, vertigo Respiratory System: asthma, dyspnea Skin and Appendages: alopecia, photosensitivity, sweating increased Special Senses: blurred vision Urogenital System: cystitis, dysuria, hematuria, interstitial nephritis, oliguria/polyuria, proteinuria, renal failure Other adverse reactions, which occur rarely are: Body as a Whole: anaphylactic reactions, appetite changes, death Cardiovascular System: arrhythmia, hypotension, myocardial infarction, palpitations, vasculitis Digestive System: colitis, eructation, fulminant hepatitis with and without jaundice, liver failure, liver necrosis, pancreatitis Hemic and Lymphatic System: agranulocytosis, hemolytic anemia, aplastic anemia, lymphadenopathy, pancytopenia Metabolic and Nutritional: hyperglycemia Nervous System: convulsions, coma, hallucinations, meningitis Respiratory System: respiratory depression, pneumonia Skin and Appendages: angioedema, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, urticaria Special Senses: conjunctivitis, hearing impairment

Monitoring parameters

  • Creatinine, potassium and blood pressure in CKD, heart failure, liver disease, dehydration or with ACE inhibitors, ARBs or diuretics. Liver enzymes within 4 to 8 weeks of starting long-term use (diclofenac hepatotoxicity warning). Kidney
  • Serum creatinine and potassium at baseline and during use in CKD, heart failure, cirrhosis, older adults, or with ACE inhibitors, ARBs or diuretics
  • Blood pressure; signs of gastrointestinal bleeding; hemoglobin if anemia symptoms
  • Liver enzymes periodically during long-term use
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

BioavailabilityAbout 55% (first-pass metabolism)
Time to peakAbout 2.3 hours
Half-lifeAbout 2.3 hours
Half-life in kidney failure (ESKD) kidneyUnchanged in kidney impairment (label)
Volume of distribution1.4 L/kg (apparent)
Protein bindingOver 99% (albumin)
Metabolism (CYP, transporters)Hepatic (CYP2C9 and others) to hydroxylated metabolites
Active metabolitesHydroxy metabolites; peak 4'-hydroxy level higher in kidney dysfunction (label)
Renal excretion kidneyAbout 65% of dose in urine as metabolites; under 1% unchanged
Dialyzability kidneyUnlikely (label)
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

Pharmacokinetic Parameters for Diclofenac PK Parameter Normal Healthy Adults (20 to 48 years) Mean Coefficient of Variation (%) Absolute bioavailability (%) [N = 7] 55 40 T max (hr) [N = 56] 2.3 69 Oral clearance (CL/F; mL/min) [N = 56] 582 23 Renal clearance (% unchanged drug in urine) [N = 7] <1 — Apparent volume of distribution (V/F;

L/kg) [N = 56] 1.4 58 Terminal half-life (hr) [N = 56] 2.3 48 Distribution The apparent volume of distribution (V/F) of diclofenac sodium is 1.4 L/kg.

Both diclofenac and its oxidative metabolites undergo glucuronidation or sulfation followed by biliary excretion.

Excretion Diclofenac is eliminated through metabolism and subsequent urinary and biliary excretion of the glucuronide and the sulfate conjugates of the metabolites.

Little or no free unchanged diclofenac is excreted in the urine.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Mechanism of Action Diclofenac has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of diclofenac sodium delayed-release tablets, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro.

Diclofenac concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because diclofenac is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.

Pharmacokinetics Absorption Diclofenac is 100% absorbed after oral administration compared to intravenous (IV) administration as measured by urine recovery. However, due to first-pass metabolism, only about 50% of the absorbed dose is systemically available (see Table 1). Food has no significant effect on the extent of diclofenac absorption.

However, there is usually a delay in the onset of absorption of 1 to 4.5 hours and a reduction in peak plasma levels of less than 20%. Table 1. Pharmacokinetic Parameters for Diclofenac PK Parameter Normal Healthy Adults (20 to 48 years) Mean Coefficient of Variation (%) Absolute bioavailability (%) [N = 7] 55 40 T max (hr) [N = 56] 2.3 69 Oral clearance (CL/F; mL/min) [N = 56] 582 23 Renal clearance (% unchanged drug in urine) [N = 7] <1 — Apparent volume of distribution (V/F; L/kg) [N = 56] 1.4 58 Terminal half-life (hr) [N = 56] 2.3 48 Distribution The apparent volume of distribution (V/F) of diclofenac sodium is 1.4 L/kg.

Diclofenac is more than 99% bound to human serum proteins, primarily to albumin. Serum protein binding is constant over the concentration range (0.15 to 105 mcg/mL) achieved with recommended doses. Diclofenac diffuses into and out of the synovial fluid. Diffusion into the joint occurs when plasma levels are higher than those in the synovial fluid, after which the process reverses and synovial fluid levels are higher than plasma levels.

It is not known whether diffusion into the joint plays a role in the effectiveness of diclofenac. Elimination Metabolism Five diclofenac metabolites have been identified in human plasma and urine. The metabolites include 4'- hydroxy-, 5-hydroxy-, 3'-hydroxy-, 4',5-dihydroxy- and 3'-hydroxy-4'-methoxy-diclofenac. The major diclofenac metabolite, 4'-hydroxy-diclofenac, has very weak pharmacologic activity.

The formation of 4’- hydroxy- diclofenac is primarily mediated by CYP2C9. Both diclofenac and its oxidative metabolites undergo glucuronidation or sulfation followed by biliary excretion. Acyl glucuronidation mediated by UGT2B7 and oxidation mediated by CYP2C8 may also play a role in diclofenac metabolism. CYP3A4 is responsible for the formation of minor metabolites, 5-hydroxy- and 3’-hydroxy-diclofenac.

In patients with renal dysfunction, peak concentrations of metabolites 4'-hydroxy- and 5-hydroxy-diclofenac were approximately 50% and 4% of the parent compound after single oral dosing compared to 27% and 1% in normal healthy subjects. Excretion Diclofenac is eliminated through metabolism and subsequent urinary and biliary excretion of the glucuronide and the sulfate conjugates of the metabolites.

Little or no free unchanged diclofenac is excreted in the urine. Approximately 65% of the dose is excreted in the urine and approximately 35% in the bile as conjugates of unchanged diclofenac plus metabolites. Because renal elimination is not a significant pathway of elimination for unchanged diclofenac, dosing adjustment in patients with mild to moderate renal dysfunction is not necessary.

The terminal half-life of unchanged diclofenac is approximately 2 hours. Special Populations Pediatric: The pharmacokinetics of diclofenac sodium delayed-release tablets has not been investigated in pediatric patients. Race: Pharmacokinetic differences due to race have not been identified. Hepatic Impairment: Hepatic metabolism accounts for almost 100% of diclofenac sodium delayed-release tablets, elimination, so patients with hepatic disease may require reduced doses of diclofenac sodium delayed-release tablets, compared to patients with normal hepatic function.

Renal Impairment: Diclofenac pharmacokinetics has been investigated in subjects with renal insufficiency. No differences in the pharmacokinetics of diclofenac have been detected in studies of patients with renal impairment. In patients with renal impairment (inulin clearance 60 to 90, 30 to 60, and less than 30 mL/min; N = 6 in each group), area under the curve (AUC) values and elimination rate were comparable to those in healthy subjects.

Drug Interactions Studies Voriconazole: When coadministered with voriconazole (inhibitor of CYP2C9, 2C19, and 3A4 enzyme), the C max and AUC of diclofenac increased by 114% and 78%, respectively (see PRECAUTIONS; Drug Interactions). Aspirin: When NSAIDs were administered with aspirin, the protein binding of NSAIDs were reduced, although the clearance of free NSAID was not altered.

The clinical significance of this interaction is not known. See Table 2 for clinically significant drug interactions of NSAIDs with aspirin (see PRECAUTIONS; Drug Interactions).

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Diclofenac 25 mg/mL, 3 mL Ampule₱7.60–₱19.90Reference ₱13.51per ampuleDPRI procurement range
Diclofenac 50 mg Tablet₱0.50–₱2.85Reference ₱0.98per tabletDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Diclofenac
PNF listingOral: 25 mg and 50 mg tablet/capsule (as sodium or potassium salt)
PNF listingOral: 50 mg enteric coated tablet or MR tablet (as sodium salt)
PNF listingOral: 100 mg MR tablet/capsule (as sodium or potassium salt)
PNF listingInj.: 25 mg/mL, 3 mL ampul (IM, IV) (as sodiumsalt)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Diclofenac Sodium · Umedica Laboratories USA Inc. [US FDA-approved label, version 7, October 23, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e5c6669-390f-4c32-b9b8-13ed3c517462
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  5. Umedica Laboratories USA Inc. (2026). Diclofenac sodium delayed-release tablets [Prescribing information; US FDA-approved label, ANDA219945, set ID 0e5c6669-390f-4c32-b9b8-13ed3c517462, version effective October 23, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e5c6669-390f-4c32-b9b8-13ed3c517462
  6. Zameer Pharmaceuticals LLC. (2025). Naproxen tablets [Prescribing information; US FDA-approved label, set ID d2e5553a-7c90-407c-9f07-3be65560c23a] (NSAID class labeling, section 7). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2e5553a-7c90-407c-9f07-3be65560c23a

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .